143 completed, 20 unknown, 4 terminated, 4 withdrawn. 79 Phase 3, 54 Phase 4, 17 Phase 2, 15 Not applicable, 14 Phase 1.
Follow Vildagliptin: new trials by email Literature Review of Vildagliptin trials Research Report on Vildagliptin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy of Vildagliptin Versus Metformin in Patients With Polycystic Ovary Syndrome Metformin, Vildagliptin (Galvus) - Poly Cystic Ovary Syndrome | Phase 2 / Phase 3 | Not yet recruiting | Tanta University | 70 | 2026-09-20 | 2026-09-21 |
| Clinical Trial of Vildagliptin in Early Parkinson's Disease Vildagliptin 50 mg bid - Parkinson's Disease | Not applicable | Not yet recruiting | First Affiliated Hospital, Sun Yat-Sen University | 66 | 2025-06-01 | 2025-04-30 |
| Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes. Metformin, Dulaglutide, Semaglutide 1.0 mg - Diabetes Mellitus Type 2 | Phase 4 | Completed | Fundación para la Investigación del Hospital Clínico de Valencia | 92 | 2025-05-26 | 2026-09-04 |
| Comparison of Once-Weekly Trelagliptin Vs. Once-Daily Vildagliptin for HbA1c Reduction in Type 2 Diabetes Trelagliptin 100 mg, Vildagliptin 50 mg - Type 2 Diabetes Mellitus (T2DM) | Not applicable | Active not recruiting | Lahore General Hospital | 102 | 2024-12-15 | 2025-03-21 |
| Comparison of Once-Weekly Trelagliptin vs. Once-Daily Vildagliptin for HbA1c Reduction in Type 2 Diabetes Trelagliptin 100 mg, Vildagliptin 50 mg - Type 2 Diabetes Mellitus (T2DM) | Not applicable | Active not recruiting | PNS Hafeez - Naval Hospital | 102 | 2024-11-15 | 2025-04-06 |
| Vildagliptin and Metformin Tablets 50/1000 mg Relative to GALVUS MET (50mg/1000 mg) Tablets Vildagliptin and Metformin-Test product, Vildagliptin and Metformin-Reference product - Healthy Subjects | Phase 1 | Unknown | Bio-innova Co., Ltd | 48 | 2024-09-05 | 2024-02-08 |
| The Bioequivalence Study of Fixed-dose Combination of Vildagliptin and Metformin HCI 50/1000 mg FCT Under Fed Conditions Vildagliptin and Metformin Hydrochloride 50mg 1000 mg Film-coated Tablets - Healthy Volunteer | Phase 1 | Unknown | International Bio service | 40 | 2024-05-23 | 2024-02-07 |
| Efficacy of Vildagliptin Versus Metformin in Poly Cystic Ovary Syndrome Metformin Hydrochloride tablet, Vildagliptin 50 MG - Poly Cystic Ovary Syndrome | Phase 2 / Phase 3 | Recruiting | October 6 University | 60 | 2023-11-25 | 2025-07-30 |
| Empagliflozin Versus Vildagliptin in CAD Patients With T2DM Empagliflozin 10 MG, Vildagliptin 50 MG - Coronary Artery Disease, Type 2 Diabetes | Not applicable | Completed | Damanhour University | 120 | 2023-08-10 | 2024-11-29 |
| Effect of Vildagliptin Versus Dapagliflozin as Add on Therapy to Metformin on Cardiovascular Risk Factors Dapagliflozin + Metformin, Vildagliptin + Metformin - Type 2 Diabetes | Phase 4 | Completed | Al-Azhar University | 196 | 2023-06-01 | 2025-07-22 |
| Oral Combination of Glimepiride/Vildagliptin/Metformin in Patients With T2D and Dual Treatment Failure A1=Glimepiride / Vildagliptin / Metformin (1 mg/ 50 mg/ 500 mg), B2=Glimepiride / Vildagliptin / Metformin (1 mg/ 50 mg/ 500 mg), (A2) Glimepiride/Vildagliptin/Metformin - Type 2 Diabetes | Phase 3 | Completed | Laboratorios Silanes S.A. de C.V. | 162 | 2023-03-21 | 2025-06-10 |
| Bioequivalence Study to Compare Metformin / Vildagliptin (850 mg/50 mg) Versus Galvumet® Metformin / Vildagliptin Film Coated Tablets (850 mg / 50 mg), Galvumet® Film Coated Tablets (850 mg / 50 mg) - Fed Conditions | Phase 1 | Completed | Reseach Laboratory of Clinical and Experimental Pharmacology | 18 | 2023-02-21 | 2023-10-27 |
| Vildagliptin Versus Glimepiride in Type 2 Diabetic Patients Vildagliptin 50 MG, Glimepiride 3 Mg Oral Tablet - Type 2 Diabetes | Not applicable | Completed | Damanhour University | 70 | 2022-10-01 | 2025-02-04 |
| The Effect of Metformin and DPP4 Inhibitors on Cognition and Cardiovascular Protection in Type 2 Diabetic Patients Vildagliptin - Type 2 Diabetes Mellitus | Unknown | MTI University | 60 | 2022-06-01 | 2022-06-23 | |
| Durable Effect of Imeglimin on the Glycemic Control in Patients With Type 2 Diabetes Mellitus Imeglimin, Metformin, Vildagliptin - Diabetes Mellitus, Type 2 | Phase 4 | Active not recruiting | National Center for Global Health and Medicine, Japan | 567 | 2022-05-26 | 2026-04-09 |
| Cognitive Protective Effect of Newer Antidiabetic Drugs Dapagliflozin, Empagliflozin, Canagliflozin - Type 2 Diabetes | Unknown | Alexandria University | 100 | 2022-03-02 | 2022-07-26 | |
| Study to Evaluate the Safety and Efficacy of PB-201 in Treatment-naive Patients With Type 2 Diabetes Mellitus PB-201, Vildagliptin, PB-201 matched placebo - Type 2 Diabetes Mellitus (T2DM) | Phase 3 | Unknown | PegBio Co., Ltd. | 672 | 2021-09-30 | 2022-02-08 |
| Anti-diabetic Drugs and Fatty Liver Management Metformin - Fatty Liver, Nonalcoholic, Diabetes Mellitus, Type 2 | Not applicable | Unknown | Alexandria University | 120 | 2021-02-23 | 2022-01-18 |
| Vildagliptin for Treatment of Antipsychotic-induced Dyslipidemia Vildagliptin 50 MG, Placebo - Schizophrenia, Dyslipidemias | Phase 2 | Withdrawn | Sadat City University | 2021-02-16 | 2025-07-14 | |
| Study to Evaluate the Effect of Metformin in the Prevention of HG in HR[+]/HER2[-] PIK3CA-mut Advanced BC Patients Alpelisib, Metformin, Fulvestrant - Breast Cancer | Phase 2 | Completed | MedSIR | 69 | 2020-10-23 | 2025-07-29 |
Showing 20 of 178. Sign in to see all of them.
Diabetes Mellitus, Type 2 (137) · Diabetes Mellitus (28) · Hypoglycemia (7) · Insulin Resistance (6) · Hyperglycemia (5) · Renal Insufficiency (4) · Diabetes Mellitus, Type 1 (3) · Glucose Intolerance (3) · Coronary Artery Disease (2) · Heart Failure (2) · Hypertension (2) · Myocardial Ischemia (2) · Non-alcoholic Fatty Liver Disease (2) · Atherosclerosis (1) · Bone Diseases, Metabolic (1)
Novartis Pharmaceuticals (48) · Novartis (43) · Lund University (4) · AET Laboratories Private Limited (3) · Canadian Network for Observational Drug Effect Studies, CNODES (3) · Damanhour University (3) · Alexandria University (2) · MTI University (2) · Merck Sharp & Dohme LLC (2) · Sadat City University (2) · University Hospital, Gentofte, Copenhagen (2) · University of Campania Luigi Vanvitelli (2) · Al-Azhar University (1) · Astellas Pharma Inc (1) · Azienda Ospedaliero-Universitaria di Parma (1)
Germany (40) · United States (31) · Egypt (17) · Japan (12) · Switzerland (12) · France (10) · China (9) · India (8) · Italy (8) · Russia (8) · South Korea (8) · Spain (7) · Brazil (6) · Canada (6) · Romania (6)
Pierre Ernst, MD, MSc (3) · Abdel Rahman M El-Naggar, Professor (1) · Adrian Vella, MD (1) · Ahmed Elshafeey, Ph.D. Pharma (1) · Ahmed F El-Yazbi, PhD (1) · Aline AF Fofonka, MSc (1)
PMID 17878242, PMID 18093207, PMID 20518805, PMID 32501595, PMID 32803882, PMID 16112958, PMID 17098089, PMID 17223217, PMID 17259484, PMID 17277036, PMID 17300592, PMID 17300593, PMID 17303799, PMID 17387446, PMID 17622601, PMID 17909087, PMID 17925336, PMID 17947341, PMID 18034842, PMID 18248490, PMID 18284434, PMID 18341596, PMID 18355325, PMID 18401832, PMID 18726829, PMID 18931099, PMID 18957505, PMID 19088168, PMID 19174497, PMID 19221978, PMID 19320662, PMID 19383032, PMID 19515542, PMID 19614942, PMID 19656312, PMID 19705345, PMID 20537746, PMID 20925938, PMID 21239518, PMID 21537424, PMID 21547496, PMID 22369287, PMID 22775317, PMID 22809630, PMID 22855332, PMID 22996038, PMID 23197976, PMID 23524641, PMID 23645885, PMID 23704713
2008 (2), 2009 (1), 2019 (1), 2025 (1)